Australian Hajj pilgrims knowledge, attitude and perception about Ebola, November 2014 to February 2015.
Australian Hajj pilgrims knowledge, attitude and perception about Ebola, November 2014 to February 2015. Euro Surveill. 2015;20(12) Authors: Alqahtani AS, Wiley KE, Willaby HW, BinDhim NF, Tashani M, Heywood AE, Booy R, Rashid H PMID: 25846489 [PubMed - in process]
A recap of Tuesday’s top stories: Pneumonia number one killer of children; Australia’s wildfires rage on; Ebola vaccine gets green light; new child labour and trafficking study; Malnutrition soars in Latin America and Caribbean; Intellectual Property chief encourages innovation.
U.S. drugmaker Merck &Co Inc on Monday received approval from the European Commission to market its Ebola vaccine.
In big global health news, the European Commission has granted Merck Sharp and Dohme B.V. marketing authorization in Europe for Ervebo.
Nature, Published online: 12 November 2019; doi:10.1038/d41586-019-03490-8The drug, which has already been given to hundreds of thousands of people in the Democratic Republic of the Congo, can now be distributed more widely.
Merck's Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.
U.S. drugmaker Merck&Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.
[Malawi News Agency] Lilongwe -The Ministry of Health and Population has stressed the need for the country to stay prepared for Ebola disease even though there has been no single confirmed case registered in the country.
The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
Johnson&Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck&Co Inc's vaccine.